Curated News
By: NewsRamp Editorial Staff
June 10, 2025
Calidi Biotherapeutics Appoints Eric Poma, PhD, as New CEO
TLDR
- Calidi Biotherapeutics appoints Eric Poma, PhD, as CEO, leveraging his oncology expertise to advance its innovative cancer therapies and secure a competitive edge in biotech.
- Calidi Biotherapeutics enhances its leadership with Dr. Eric Poma as CEO, aiming to systematically progress its stem cell-based cancer treatments through clinical development.
- Calidi Biotherapeutics' new CEO, Dr. Eric Poma, is set to drive forward therapies that could significantly improve cancer treatment outcomes and patient safety worldwide.
- Discover how Calidi Biotherapeutics' strategic CEO appointment could revolutionize cancer treatment with cutting-edge stem cell and virotherapy technologies.
Impact - Why it Matters
This news is significant as it highlights a pivotal leadership change at Calidi Biotherapeutics, a company pioneering innovative cancer treatments. Dr. Poma's appointment could accelerate the development and commercialization of Calidi's therapies, potentially offering new hope for patients with high-grade gliomas and solid tumors. The advancements in targeted antitumor virotherapies represent a breakthrough in oncology, emphasizing the importance of this development for the medical community and patients alike.
Summary
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage immuno-oncology company, has announced the appointment of Eric Poma, PhD, as its new chief executive officer and board member. This strategic move aims to leverage Dr. Poma's extensive experience in oncology, fundraising, and strategic partnerships to advance Calidi's innovative therapies towards commercialization. The company specializes in developing targeted antitumor virotherapies using proprietary stem cell-based platforms to fight cancer, including high-grade gliomas and solid tumors. For more details, visit the full article.
Calidi Biotherapeutics is at the forefront of creating off-the-shelf, universal cell-based delivery platforms designed to enhance the efficacy and safety of oncolytic viruses. Their work represents a significant step forward in the treatment of metastatic diseases. The company's headquarters are in San Diego, California, and more information can be found at www.calidibio.com. Additionally, updates on CLDI are available in the company’s newsroom at https://ibn.fm/CLDI.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Calidi Biotherapeutics Appoints Eric Poma, PhD, as New CEO
